Connect with us
[the_ad id="89560"]

COVID-19

Rep. Paul Gosar introduces bill to end vaccine manufacturer immunity from injury lawsuits

Published

7 months ago

5 minute read

From LifeSiteNews

By Calvin Freiburger

Rep. Paul Gosar’s End the Vaccine Carveout Act would eliminate the general immunity vaccine manufacturers enjoy from vaccine injury civil suits under the federal National Childhood Vaccine Injury Act of 1986.

Republican U.S. Rep. Paul Gosar of Arizona introduced a bill Thursday that would end pharmaceutical companies’ shield against liability for any potential harmful effects of the vaccines they manufacture.

 H.R. 9828, the End the Vaccine Carveout Act, would allow individuals to “bring a civil action against a vaccine administrator or manufacturer in a State or Federal court for damages arising from such injury or death,” according to an advance copy of the text provided to LifeSiteNews.

This would eliminate the general immunity vaccine manufacturers enjoy under the federal National Childhood Vaccine Injury Act of 1986, which instead establishes a compensation program for victims. Gosar’s bill allows for civil actions to be pursued regardless of whether a victim has filed a petition with the program, although ultimately receiving an award from one would invalidate a petition to the other.

“Government bureaucrats and scientists responsible for approving vaccines are in bed with Big Pharma, often owning pharmaceutical stocks, serving as consultants and receiving lucrative contracts from pharmaceutical companies that pressure them to produce favorable results which is in direct violation of federal law,” Gosar said in a press release. “Big Pharma doesn’t deserve a get-out-of-jail-free card for injuries caused by their harmful vaccines.”

The question of vaccine safety has become more mainstream in recent years due to the controversy surrounding the COVID-19 vaccines, which were developed and reviewed in a fraction of the time  vaccines usually take under the Trump administration’s Operation Warp Speed initiative.

A large body of evidence identifies significant risks to the COVID vaccines. Among it, the federal Vaccine Adverse Event Reporting System (VAERS) reports 37,910 deaths, 217,931 hospitalizations, 21,917 heart attacks, and 28,602 myocarditis and pericarditis cases as of September 6, among other ailments. U.S. Centers for Disease Control and Prevention (CDC) researchers have recognized a “high verification rate of reports of myocarditis to VAERS after mRNA-based COVID-19 vaccination,” leading to the conclusion that “under-reporting is more likely” than over-reporting.

An analysis of 99 million people across eight countries published February in the journal Vaccine  “observed significantly higher risks of myocarditis following the first, second and third doses” of mRNA-based COVID vaccines, as well as signs of increased risk of “pericarditis, Guillain-Barré syndrome, and cerebral venous sinus thrombosis,” and other “potential safety signals that require further investigation.” In April, the CDC was forced to release by court order 780,000 previously undisclosed reports of serious adverse reactions, and a study out of Japan found “statistically significant increases” in cancer deaths after third doses of mRNA-based COVID-19 vaccines, and offered several theories for a causal link.

In Florida, an ongoing grand jury investigation into the vaccines’ manufacturers is slated to release a highly anticipated report on the shots, and a lawsuit by the state of Kansas has been filed accusing Pfizer of misrepresentation for calling the shots “safe and effective.”

According to the Congressional Research Service (CRS), the PREP Act empowers the federal government to “limit legal liability for losses relating to the administration of medical countermeasures such as diagnostics, treatments, and vaccines.” Near the beginning of the 2020 COVID-19 outbreak, the Trump administration invoked the Act in declaring the virus a “public health emergency.”

Under this “sweeping” immunity, CRS explained, the federal government, state governments, “manufacturers and distributors of covered countermeasures,” and licensed or otherwise-authorized health professionals distributing those countermeasures are shielded from “all claims of loss” stemming from those countermeasures, with the exception of “death or serious physical injury” brought about through “willful misconduct,” a standard that, among other hurdles, requires the offender to have acted “intentionally to achieve a wrongful purpose.”

Many hope that by going after Big Pharma for misrepresentations surrounding their products rather than the products themselves, efforts like the Kansas suit can circumvent that hurdle to impose consequences on those responsible for the shots.

Related Topics:

Todayville is a digital media and technology company. We profile unique stories and events in our community. Register and promote your community event for free.

Follow Author

More from this author
Business / 15 mins ago

Who owns Canada’s public debt?

Alberta / 29 mins ago

Bonnyville RCMP targeted by suspect driving a trackhoe

Business / 2 hours ago

BUILD CANADA NOW: An Open Letter to the Prime Minister of Canada from Energy Leaders

COVID-19

Tulsi Gabbard says US funded ‘gain-of-function’ research at Wuhan lab at heart of COVID ‘leak’

Published on May 3, 2025

By

From LifeSiteNews

By Conservative Treehouse

The director of National Intelligence revealed gain-of-function ties to US funding, which could indicate that the US helped bankroll the supposed COVID lab leak.

In this segment of a remarkable interview by Megyn Kelly, Director of National Intelligence Tulsi Gabbard discusses the current Intelligence Community (IC) research into the origin of the SARS-CoV-2 pandemic (aka, COVID-19).

Gabbard talks about the U.S. government funding of “gain-of-function” research, which is a soft sounding phrase to describe the weaponization of biological agents.

Gabbard notes the gain-of-function research taking place in the Wuhan lab was coordinated and funded by the United States government, and the IC is close to making a direct link between the research and the release of the COVID-19 virus.

Additionally, Gabbard explains the concern of other biolabs around the world and then gets very close to the line of admitting the IC itself is politically weaponized (which it is but would be stunning to admit).

 

Continue Reading

COVID-19

Study finds Pfizer COVID vaccine poses 37% greater mortality risk than Moderna

Published on May 1, 2025

By

From LifeSiteNews

By Nicolas Hulscher, MPH

A study of 1.47 million Florida adults by MIT’s Retsef Levi and Surgeon General Joseph Ladapo finds significantly higher all-cause mortality after Pfizer vaccination compared to Moderna

A new study of 1.47 million Florida adults by MIT’s Retsef Levi and Surgeon General Joseph Ladapo finds significantly higher all-cause, cardiovascular, and COVID-19 mortality after Pfizer vaccination.

The study titled “Twelve-Month All-Cause Mortality after Initial COVID-19 Vaccination with Pfizer-BioNTech or mRNA-1273 among Adults Living in Florida” was just uploaded to the MedRxiv preprint server. This study was headed by MIT Professor Retsef Levi, with Florida Surgeon General Dr. Joseph Ladapo serving as senior author:

Study Overview

  • Population: 1,470,100 noninstitutionalized Florida adults (735,050 Pfizer recipients and 735,050 Moderna recipients).
  • Intervention: Two doses of either:
    • BNT162b2 (Pfizer-BioNTech)
    • mRNA-1273 (Moderna)
  • Follow-up Duration: 12 months after second dose.
  • Comparison: Head-to-head between Pfizer vs. Moderna recipients.
  • Main Outcomes:
    • All-cause mortality
    • Cardiovascular mortality
    • COVID-19 mortality
    • Non-COVID-19 mortality

All-cause mortality

Pfizer recipients had a significantly higher 12-month all-cause death rate than Moderna recipients — about 37% higher risk.

  • Pfizer Risk: 847.2 deaths per 100,000 people
  • Moderna Risk: 617.9 deaths per 100,000 people
  • Risk Difference:
    ➔ +229.2 deaths per 100,000 (Pfizer excess)
  • Risk Ratio (RR):
    ➔ 1.37 (i.e., 37% higher mortality risk with Pfizer)
  • Odds Ratio (Adjusted):
    ➔ 1.384 (95% CI: 1.331–1.439)

Cardiovascular mortality

Pfizer recipients had a 53% higher risk of dying from cardiovascular causes compared to Moderna recipients.

  • Pfizer Risk: 248.7 deaths per 100,000 people
  • Moderna Risk: 162.4 deaths per 100,000 people
  • Risk Difference:
    ➔ +86.3 deaths per 100,000 (Pfizer excess)
  • Risk Ratio (RR):
    ➔ 1.53 (i.e., 53% higher cardiovascular mortality risk)
  • Odds Ratio (Adjusted):
    ➔ 1.540 (95% CI: 1.431–1.657)

COVID-19 mortality

Pfizer recipients had nearly double the risk of COVID-19 death compared to Moderna recipients.

  • Pfizer Risk: 55.5 deaths per 100,000 people
  • Moderna Risk: 29.5 deaths per 100,000 people
  • Risk Difference:
    ➔ +26.0 deaths per 100,000 (Pfizer excess)
  • Risk Ratio (RR):
    ➔ 1.88 (i.e., 88% higher COVID-19 mortality risk)
  • Odds Ratio (Adjusted):
    ➔ 1.882 (95% CI: 1.596–2.220)

Non-COVID-19 mortality

Pfizer recipients faced a 35% higher risk of dying from non-COVID causes compared to Moderna recipients.

  • Pfizer Risk: 791.6 deaths per 100,000 people
  • Moderna Risk: 588.4 deaths per 100,000 people
  • Risk Difference:
    ➔ +203.3 deaths per 100,000 (Pfizer excess)
  • Risk Ratio (RR):
    ➔ 1.35 (i.e., 35% higher non-COVID mortality risk)
  • Odds Ratio (Adjusted):
    ➔ 1.356 (95% CI: 1.303–1.412)

Biological explanations

The findings of this study are surprising, given that Moderna’s mRNA-1273 vaccine contains approximately three times more mRNA (100 µg) than Pfizer’s BNT162b2 vaccine (30 µg). This suggests that the higher mortality observed among Pfizer recipients could potentially be related to higher levels of DNA contamination — an issue that has been consistently reported worldwide:

The paper hypothesizes differences between Pfizer and Moderna may be due to:

  • Different lipid nanoparticle compositions
  • Differences in manufacturing, biodistribution, or storage conditions

Final conclusion

Florida adults who received Pfizer’s BNT162b2 vaccine had higher 12-month risks of all-cause, cardiovascular, COVID-19, and non-COVID-19 mortality compared to Moderna’s mRNA-1273 vaccine recipients.

Unfortunately, without an unvaccinated group, the study cannot determine the absolute increase in mortality risk attributable to mRNA vaccination itself. However, based on the mountain of existing evidence, it is likely that an unvaccinated cohort would have experienced much lower mortality risks. It’s also important to remember that Moderna mRNA injections are still dangerous.

As the authors conclude:

These findings are suggestive of differential non-specific effects of the BNT162b2 and mRNA-1273 COVID-19 vaccines, and potential concerning adverse effects on all-cause and cardiovascular mortality. They underscore the need to evaluate vaccines using clinical endpoints that extend beyond their targeted diseases.

Nicolas Hulscher, MPH

Epidemiologist and Foundation Administrator, McCullough Foundation

www.mcculloughfnd.org

Please consider following both the McCullough Foundation and my personal accounton X (formerly Twitter) for further content.

Reprinted with permission from Focal Points.

Continue Reading

Trending

X